Sevoflurane-sparing degree of dexmedetomidine in patients with gynecological laparoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004815

Enrollment

Unknown

Registered

2014-06-10

Start date

2014-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with gynecological laparoscopy

Interventions

Group C:intravenously infuse the same amount of normal saline

Group D:Intravenous infusion of dexmedetomidine 1.0 ug/kg by 10 min before anesthesia induction, followed by 0.4 ug/kg/h continuous infusion to the end of the surgery

Eligibility

Sex/Gender

All

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective gynecological laparoscopy; 2. BMI 18.5~24.0 kg/m2; 3. ASA physical status I or II.

Exclusion criteria

Exclusion criteria: 1. Smoking history; 2. History of hypertension and diabetes; 3. The central nervous system lesions; 4. Halide drug allergy history and family history of malignant hyperthermia; 5. Operation History; 6. Liver and kidney dysfunction; 7. Taking sedatives 2 d preoperatively.

Design outcomes

Primary

Measure	Time frame
sevoflurane consumption per unit of time;occurrence of intraoperative awareness;	—

Secondary

Measure	Time frame
end-tidal concentration of sevoflurane;MAP and HR;time of recovery;time of removal laryngeal mask airway;incidence of postoperative agitatio;	—

Countries

China

Contacts

Public ContactLi Juan

Anhui Provincial Hospital

huamuzi1999@126.com+86 13956005465

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026